DJIA 16,985.61 78.99 0.47%
NASDAQ 4,419.03 27.57 0.63%
S&P 500 1,972.83 9.12 0.46%
market minute promo

PHARMACYCLICS, INC. (NASDAQ: PCYC)

95.93 0.61 (0.64%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PCYC $95.93 0.64%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $94.94
Previous Close $95.32
Daily Range $93.00 - $96.10
52-Week Range $82.51 - $154.89
Market Cap $7.2B
P/E Ratio 52.09
Dividend (Yield) $0.00 (0.0%)
Volume 963,541
Average Daily Volume 1,192,700
Current FY EPS $0.30

Sector

Healthcare

Industry

Drugs

PHARMACYCLICS, INC. (PCYC) Description

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases. Website: http://www.pharmacyclics.com/

News & Commentary Rss Feed

1 Drug Critical to Johnson & Johnson's Future Success

The recent approval of Johnson (JNJ) and Pharmacyclics (PCYC) Imbruvica for two forms of blood cancer may be just the beginning.

Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatm

Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment

3 Stocks Spiking on Unusual Volume

Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics

Fire Up The Immuno-Oncology Powerhouses: John McCamant

Pharmacyclics' Imbruvica Under FDA Priority Review - Analyst Blog

Large Cap Biotech Stocks to Buy Leading the Comeback Rally

PCYC, ALXN And PFE, 3 Drugs Stocks Pushing The Industry Lower

Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog

Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog

UPDATE: Morgan Stanley Reiterates On Pharmacyclics Following Investor Event

Encouraging Data on Pharmacyclics/J&J Drug - Analyst Blog

See More PCYC News...

PCYC's Top Competitors

PCYC $95.93 (0.64%)
Current stock: PCYC
AMGN $119.57 (-0.33%)
Current stock: AMGN
GILD $88.68 (1.80%)
Current stock: GILD
BIIB $320.14 (0.80%)
Current stock: BIIB